BeiGene Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$529.6M
Industry:Biotech
Founded:N/A
Lead Investor(s):N/A

Industry Ranking

Estimated Revenue & Financials

  • BeiGene's estimated annual revenue is currently $180.4M per year.
  • BeiGene received $800.0M in venture funding in January 2018.
  • BeiGene's estimated revenue per employee is $155,000
  • BeiGene's total funding is $529.6M.

Employee Data

  • BeiGene has 1164 Employees.
  • BeiGene grew their employee count by 44% last year.
  • BeiGene currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Ultivue
$8.7M56-12%N/A-N/A
Ohana Bioscienc...
$8.7M5660%N/A-N/A
Compass Therape...
$16.4M10614%N/A-N/A
Cell Signaling ...
$89.4M577N/AN/A-N/A
Momenta Pharmac...
N/A220N/AN/A-N/A
Emulate
$15.3M99-17%N/A-N/A
ArQule
N/A94N/AN/A-N/A
Hamilton Storag...
$17.2M1119%N/A-N/A
Alnylam Pharmac...
$74.9M127731%N/A-N/A
Transgenomic
N/A47N/AN/A-N/A
Missing a competitor? Contribute!?
Submit

BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States (Cambridge, MA; Fort Lee, NJ; Emeryville, CA & San Mateo, CA), Switzerland and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. For more information, see www.beigene.com.

keywords:Biotechnology,Healthcare

1164

Number of Employees

$180.4M

Revenue (est)

1

Current Jobs

44%

Employee Growth %

$529.6M

Total Funding

N/A

Valuation

N/A

Accelerator

B2C

Type

BeiGene News

09/03/2019 - BeiGene Shares Continue Slide After Short Seller Report

J Capital alleged that BeiGene has been stuck with an unsellable product, Celgene, of which actual sales were 57 percent lower than it ...

09/08/2019 - Beigene (NASDAQ:BGNE) Trading Down 6.8% After Insider Selling

Beigene Ltd (NASDAQ:BGNE)'s share price traded down 6.8% during mid-day trading on Thursday after an insider sold shares in the company ...

09/03/2019 - Here's The Case for and Against BeiGene, Ltd. (BGNE)

On Thursday, shares of BeiGene, Ltd. (NASDAQ:BGNE) marked $131.03 per share versus a previous $140.56 closing price. With having a ...

BeiGene Funding

DateAmountRoundLead InvestorsReference
2016-11-15$150.0MUndisclosedArticle
2018-01-19$800.0MUndisclosedMultipleArticle

BeiGene Executive Hires

DateNameTitleReference
2016-05-05Ji LiEVP & Global Head Business DevelopmentArticle
2016-08-25Amy PetersonChief Medical Officer, Immuno-oncologyArticle
2016-09-07Jane HuangChief Medical Officer, HematologyArticle
2016-10-04Ross PettitSVP Global Development OperationsArticle
2018-05-02Xiaobin WuGeneral Manager of China/PresidentArticle